ALT GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Altimmune Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.
Did you know?
Currently operating at a negative 244702.8% profit margin.
Current Price
$2.82
+8.46%GoodMoat Value
$0.00
99.9% overvaluedProfile
Valuation (TTM)
Market Cap$294.00M
P/E-3.34
EV—
P/B1.31
Shares Out104.25M
P/Sales8166.58
Revenue$36000.00
EV/EBITDA—
Altimmune Inc (ALT) Quality Analysis
ALT Profitability
Profitability trend analysis coming soon
ALT Growth
Growth trend analysis coming soon
ALT Financial Health
Financial health indicators coming soon
ALT Quality & Fundamental Analysis
Altimmune Inc (ALT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Altimmune Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Altimmune Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -244702.78% and a return on equity (ROE) of -39.17%. Return on assets (ROA) stands at -31.47%.
The debt-to-equity ratio is 0.15, with a current ratio of 18.55. Operating margin is -230460.98%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Altimmune Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.